US FDA approves herpes zoster vaccine for adults aged 50 years and older


eMediNexus    24 October 2017

The US FDA has approved recombinant zoster vaccine (adjuvanted) to prevent herpes zoster in adults aged 50 years and older. The vaccine, Shingrix, includes glycoprotein E, an antigen and AS01B, an adjuvant system. It is to be administered in two doses, at a gap of 2-6 months.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.